The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1).
 
Julie R. Brahmer
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck KGaA
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
Other Relationship - Bristol-Myers Squibb
 
Edward S. Kim
Honoraria - Celgene; Lilly; Myriad Genetics
Consulting or Advisory Role - Celgene; Lilly; Myriad Genetics
Research Funding - Lilly
 
Jin Zhang
Employment - Merck
 
Margaret Marie Smith
Employment - Merck
 
Reshma A. Rangwala
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Mary E.R. O'Brien
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Pierre Fabre
Speakers' Bureau - Boehringer Ingelheim; Pierre Fabre